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The Rio Grande Valley (RGV) in South Texas has one of the highest prevalence of obesity
and type 2 diabetes (T2D) in the United States (US). We report for the first time the T2D
prevalence in persons with HIV (PWH) in the RGV and the interrelationship between T2D,
cardiometabolic risk factors, HIV-related indices, and antiretroviral therapies (ART). The
PWH in this study received medical care at Valley AIDS Council (VAC) clinic sites located in
Harlingen and McAllen, Texas. Henceforth, this cohort will be referred to as Valley AIDS
Council Cohort (VACC). Cross-sectional analyses were conducted using retrospective
data obtained from 1,827 registries. It included demographic and anthropometric
variables, cardiometabolic traits, and HIV-related virological and immunological indices.
For descriptive statistics, we used mean values of the quantitative variables from
unbalanced visits across 20 months. Robust regression methods were used to determine
the associations. For comparisons, we used cardiometabolic trait data obtained from
HIV-uninfected San Antonio Mexican American Family Studies (SAMAFS; N = 2,498),
and the Mexican American population in the National Health and Nutrition Examination
Survey (HHANES; N = 5,989). The prevalence of T2D in VACC was 51% compared
to 27% in SAMAFS and 19% in HHANES, respectively. The PWH with T2D in VACC
were younger (4.7 years) and had lower BMI (BMI 2.43 units less) when compared to
SAMAFS individuals. In contrast, VACC individuals had increased blood pressure and
dyslipidemia. The increased T2D prevalence in VACC was independent of BMI. Within the
VACC, ART was associated with viral load and CD4+ T cell counts but not with metabolic
dysfunction. Notably, we found that individuals with any INSTI combination had higher
T2D risk: OR 2.08 (95%CI 1.67, 2.6; p < 0.001). In summary, our results suggest that
VACC individuals may develop T2D at younger ages independent of obesity. The high
burden of T2D in these individuals necessitates rigorously designed longitudinal studies
to draw potential causal inferences and develop better treatment regimens.
Keywords: South Texas, AIDS, type 2 diabetes, HIV, Mexican Americans, antiretroviral treatment, Rio Grande Valley,
obesity
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INTRODUCTION

This is of great concern as a majority of MAs are overweight
or obese with increased genetic susceptibility to T2D and other
metabolic diseases and, when infected with HIV, may have a
poorer response to T2D medications compared to non-Hispanic
whites (7). The increased risk to T2D could be attributed to a
family history of diabetes, impaired glucose tolerance, obesity,
insulin resistance, and genetic factors.
The Rio Grande Valley (RGV) of South Texas has one of the
highest prevalence rates of obesity and T2D in the US (8, 9).
Thus, the intersection of HIV-1 infection and metabolic disorders
such as T2D impose enormous health burden in the PWH in the
RGV. However, there is a lack of focused studies in the PWH in
the RGV especially with regard to complications arising due to
ART and their management. This is important as the Hispanics
in the RGV, a majority of whom are Mexican Americans (10),
face unique socio-economic challenges and cultural practices
and have a genetic predisposition to develop metabolic diseases.
Here, we report for the first time the prevalence of T2D and
its associated risk factors in PWH in the RGV, who are all
enrolled at a single clinic, and contrast them with the HIVnegative Mexican Americans in the US and South Texas. We also
report the interrelationship between cardiometabolic risk factors,
T2D risk, HIV viral load, various immunological parameters, and
treatment regimens in this cohort.

Current antiretroviral therapies (ART) have dramatically
improved the quality of life and increased the life span of persons
with HIV (PWH). However, when compared to the general
population, PWH have an increased incidence of common ageassociated degenerative diseases, including metabolic disorders
such as type 2 diabetes (T2D) and cardiovascular disease (CVD).
The Hispanic/Latino community comprises ∼23% of the PWH
and 27% of the ∼36,400 newly diagnosed HIV cases in the
US in 2018. A recent study estimated that the median Latino
disparity in the HIV prevalence to be 2.4 (1). Hispanics also
have a higher prevalence of cardiometabolic risk factors that
predispose them to T2D when compared to non-Hispanic whites
(NHW). For example, Lorenzo et al. compared the non-HIV
infected Mexican American population with non-Hispanic
whites, using Matsuda and insulinogenic indexes to assess
insulin resistance. They showed that Mexican Americans have
an odds ratio of 2.3 (95%CI 1.5, 3.34) for insulin resistance (2).
Thus, HIV-1 infected Hispanics are at an even greater risk of
developing T2D and T2D-related complications. However, few
studies have systematically examined the incidence of these
metabolic disorders in HIV-infected Hispanics, especially in the
U.S.-Mexico border region who encounter unique socio-cultural,
economic, migration-related challenges.
Prior to the introduction of the new generation of ART,
the incidence of diabetes was found to be 4-fold higher in
HIV-positive men when compared to HIV-negative men in the
Multicenter AIDS Cohort Study (MACS) (3). While the recent
ART regimens have less dramatic effects, there appears to be
growing evidence of increasing T2D prevalence in HIV-positive
individuals in the US. In a recent large cross-sectional study (N =
17,946,580) that included 90,900 persons with HIV (60.8% male),
Birabaharan et al. found that the overall prevalence of T2D in
the HIV group was 22.1% (N = 20,080) which is much higher
than the T2D prevalence in the US population which is 14.9%.
Notably, the prevalence of T2D was higher in the group classified
as “others,” which includes the Hispanic population (27.6 vs.
21.3% in the white population). Nansseu et al. performed a
systematic review and metanalysis of 44 studies conducted across
the globe and projected that in a “cohort of 1,000 PWH starting
ART, about 50 may have T2D after 3.7 years of follow-up while
around 457 may develop prediabetes within the same period”
(4). Other metabolic abnormalities that predispose HIV-infected
individuals to T2D have also been reported with currently used
ART regimens. A recent large-scale study (N = 14,084) showed
that 22% of lean PWH individuals became overweight just after
3 years on ART (5). A similar trend was observed in overweight
people who became obese. In another study, Sax et al. performed
a pooled analysis of weight gain in eight randomized controlled
clinical trials of treatment-naïve PWH (N = ∼5,000) and found
that demographic factors (e.g., female, black), HIV related factors
at the start of the treatment (e.g., low CD4, high viral load), and
ART regimen used may play a role in weight gain (6). Thus,
the contributions to weight gain in ART-treated PWH could be
multifactorial, and both HIV/ART and traditional risk factors
could lead to increased weight gain and metabolic risk in PWH.
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METHODS
The Valley AIDS Council Cohort
All the individuals received medical care under the supervision
of two physicians at the two Valley AIDS Council (VAC)
clinic sites located in Harlingen and McAllen, TX. The RGV
mainly comprises of four counties (Cameron, Hidalgo, Starr, and
Willacy) that are in the Southeastern region of Texas bordering
Mexico and the overall percentage of Hispanics is ∼90% (10).
Henceforth, this cohort of PWH in the RGV will be referred
to as the Valley AIDS Council Cohort (VACC). The VAC is
the only Ryan White funded agency providing medical care
and supportive services for people living with HIV/AIDS in
regions of Texas that are south and east of San Antonio, TX,
including the cities of Corpus Christi, McAllen, Harlingen and
Brownsville. In 1994, a Ryan White Title III grant enabled the
agency to provide primary health care for HIV/AIDS patients in
this region, as a primary healthcare outpatient clinic. The VAC
has provided continuous services, including HIV testing and
prevention efforts, since its start in 1987 and currently serves a
large patient population (∼2,000).

Data Collection
Valley AIDS Council Cohort
All analyses were conducted using deidentified data extracted
from a retrospective database using protocols approved by the
Institutional Review Board (IRB) of the University of Texas
Rio Grande Valley (UTRGV). The VAC houses four servers
at the Westbrook Clinic in Harlingen that work in tandem
to run eClinicalWorks (Electronic Medical Records). The VAC
also uses ARIES (AIDS Regional Information and Evaluation
System) and CMBHS (Clinical Management for Behavioral
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Health Services), both of which are State databases where
patient information is entered as part of the clinical routine.
A total of 1,827 records with unique IDs were abstracted from
medical charts which were documented between November
2017–October 2019. The following variables were extracted
from the database: demographic (age, sex, and marital status),
anthropometric [height, weight, and body mass index (BMI)] and
cardiometabolic traits (blood pressure, fasting glucose, HbA1c,
and lipids), and HIV-related virological and immunological
indices (viral load, absolute and relative CD4+ and CD8+ T
cell counts, and CD4/CD8 ratio). For analysis, the WHO obesity
classification system based on BMI (computed with kg/m2 and
categorized as normal weight <25, overweight between 25 and
30, obesity class I between 30 and 35, class II between 35 and 40
and class III >40) was used (11). We used the ADA definition for
defining T2D, which includes one of the following conditions: a
clinical history of T2D, a fasting glucose ≥ 126 mg/dL, or HbA1C
> 6.4% (12).

and associated cardiometabolic data were considered for the
analysis (N = 2,498). The NHANES data were derived from
the surveys conducted during 2017–2018. The HHANES data
included measured glucose, HbA1c, blood pressure, triglycerides,
and HDL-C for comparison with VACC. The T2D status for the
individuals enrolled in NHANES was obtained from the publicly
available databases (23).

Statistical Analyses
We used 1,827 entries from VACC for cross-sectional data
analyses. We used mean values of the quantitative variables
from unbalanced visits across 20 months. Continuous variables
were aggregated to obtain mean values and if necessary, were
transformed to obtain normal distributions. An illustrative
example of square root transformation to normalize CD4 counts
is shown in Supplementary Figure 1. Descriptive statistics were
used to evaluate the demographic and biochemical variables
related to T2D and cardiometabolic risk factors in the VACC.
Student t-tests, adjusted for variance, were performed to contrast
PWH with and without T2D. Robust regression methods with
robust Huber-White sandwich method HC3 (an approximation
to a jackknife estimator using squared residuals divided by
the square of 1-h, the letter “h” represents the leverage values
in the “hat” matrix) were used to determine the associations
between various immunological and HIV-related indices (24).
The association between the treatment regimen and T2D, and
various cardiometabolic risk factors, i.e.,: LDL-C higher than
110 mg/dL, systolic blood pressure > 140 mmHg, diastolic
blood pressure > 90 mmHg, and HDL-C adjusted by sex
(females <50 mg/dL and males <40 mg/dL) were performed
using logistic regression to obtain odds ratios (ORs) (95%
CI). Each model was adjusted by sex, age, WHO BMI
categories, viral loads (<50 copies/mL, between 50 and 1,000
copies/mL; and >1,000 copies/mL), and absolute CD4+ counts
(<500 cells/mm3 , between 500 and 900 cells/mm3 , and >900
cells/mm3 ). A backward stepwise regression with p-values < 0.20
was performed. The variables collected from the VACC were
compared with the cardiometabolic trait data from SAMAFS (N
= 2,498) after adjusting for pedigree structure and the HHANES
data (N = 5,989) using robust regressions. Descriptive statistics
such as means, standard deviations, and frequencies were used
to compare VACC, SAMAFS, and HHANES data. ANOVA with
robust HC3 method was used for comparing the continuous
variables between the three cohorts after adjusting for pedigree
structure. All analyses were performed with STATA/SE 16.0
(Stata Corp. LLC. College Station TX. USA).

San Antonio Mexican American Family Studies and
NHANES 2018 Data
For comparison with the VACC, we used data from known HIV1 negative cohorts with Mexican American ancestry, namely
the San Antonio Mexican American Family Studies (SAMAFS)
and a subset of National Health and Nutrition Examination
Survey (NHANES) individuals with reported Mexican American
ancestry, henceforth referred to as the Hispanic Health and
Nutrition Examination Survey (HHANES). The SAMAFS refers
to the combination of two San Antonio-based family studies
called the San Antonio Family Heart Study (SAFHS) (13, 14)
and the San Antonio Family Diabetes and Gallbladder Study
(SAFDGS) (15, 16). The SAFHS included 1,431 individuals in 42
large pedigrees at baseline from low-income Mexican Americans
selected at random without regard to the presence or absence of
disease. The SAFDGS enrolled 579 individuals distributed across
32 large pedigrees at baseline. These families were ascertained by
probands with T2D who were low-income Mexican American
men and women. Both study-specific protocols were approved
by the IRBs of the University of Texas Health San Antonio
(UTHSA) and the UTRGV. The major objective of SAMAFS
was to investigate the genetics of complex diseases such as T2D,
CVD, obesity and their related traits such as BMI, glucose,
insulin, lipids, and blood pressure measures using standard
protocols (14, 17–20). The T2D status was diagnosed according
to the criteria of the World Health Organization: fasting glucose
levels ≥ 126 mg/dL and/or 2-h glucose levels ≥ 200 mg/dL
(21) and/or the American Diabetes Association criteria: fasting
glucose levels ≥ 126 mg/dL (22). Participants who did not meet
these criteria but who reported that they were under treatment
with either oral antidiabetic agents or insulin and who gave
a history of diabetes were also considered to have T2D. The
SAMAFS participants have been followed in a mixed longitudinal
fashion, up to a maximum of five visits. The original families
have been expanded through additional recruitment and eight
new families were added (i.e., SAFDGS) over the years. The data
used for this study correspond to those measured at the last
clinic examination, and individuals with T2D status information

Frontiers in Medicine | www.frontiersin.org

RESULTS
Descriptive Statistics of the VACC
We extracted a total of 2,959 entries from the patient registries in
the VAC database, out of which 1,827 entries were suitable for
further analysis. All entries were from patient registries in the
VAC database entered between November 2017 to October 2019.
However, not all variables were available for each registry, and
the sample size varied from trait to trait based on the available
information. Hence, maximal information was provided for a
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TABLE 1 | General description of the Valley AIDS Council Cohort (VACC).
Variables

All Individuals

Females

Males

N

Mean ± SD

N

Mean ± SD

N

p-value

Mean ± SD

Age (years)

1,701

42.5 (12.6)

342

44.6 (12.3)

1,359

42 (12.7)

BMI

1,637

29.4 (6.1)

329

31.8 (7.1)

1,308

28.8 (5.6)

<0.001

SBP¶ (mmHg)

1,696

128.8 (13.2)

341

124.6 (15.5)

1,355

129.8 (12.3)

<0.001
<0.001

<0.001

DBP (mmHg)

1,696

80.6 (7.9)

341

78 (7.8)

1,355

81.3 (7.7)

Triglycerides (mg/dL)

1,438

177.6 (123.3)

301

168.4 (155.9)

1,137

180 (113)

0.144

HDL-C (mg/dL)

1,437

44.7 (12.4)

301

49.7 (12.1)

1,136

43.3 (12.1)

<0.001

LDL-C (mg/dL)

1,425

97.7 (28.1)

299

98.7 (28.9)

1,126

97.4 (27.9)

0.506

Abs CD4 per mm3

1,392

597.9 (308.4)

296

638.7 (302.4)

1,096

587 (309.2)

0.01

Abs CD8 per mm3

1,349

900.9 (401.8)

288

803.9 (366.8)

1,061

927.2 (407)

<0.001

CD4%

1,391

27.7 (11.1)

296

31.5 (11.2)

1,095

26.7 (10.8)

<0.001

CD8%

1,350

42.8 (12.5)

288

40.2 (12.3)

1,062

43.5 (12.4)

<0.001

CD4/CD8

1,417

0.77 (0.49)

299

0.95 (0.55)

1,118

0.73 (0.46)

<0.001

The table shows total/combined and sex-wise mean values of the demographic and clinical characteristics.
¶ SBP, systolic blood pressure; DBP, diastolic blood pressure; Abs, absolute values.

TABLE 2 | Factors associated with laboratory immunological parameters in the VACC¶ .
Predictors

Abs CD4+

Abs CD8+

CD4%

CD8%

CD4/CD8 ratio

HIV load (cat)†

−2.960 (0.259)*

0.047 (0.019)*

−4.624 (0.418)*

6.088 (0.524)*

−0.131 (0.009)*

Sex

−0.927 (0.427)*

0.147 (0.032)*

−4.244 (0.759)*

2.855 (0.797)*

−0.108 (0.019)*

BMI

0.481 (0.165)*

0.028 (0.011)*

0.305 (0.275)

−0.256 (0.291)

0.007 (0.007)

T2D

−0.552 (0.347)

−0.001 (0.024)

−0.268 (0.599)

1.505 (0.659)*

−0.018 (0.014)

Time attendance
Age

0.185 (0.079)*

−0.003 (0.006)

0.435 (0.128)*

−0.232 (0.155)

0.011 (0.003)*

−0.066 (0.014)*

−0.006 (0.001)*

−0.060 (0.023)*

−0.061 (0.027)*

−0.001 (0.001)

LDL-C

0.013 (0.006)*

0.001 (0.001)

0.01 (0.01)

−0.011 (0.012)

0.001 (0.001)

Triglycerides

0.002 (0.002)

0.001 (0.001)*

−0.005 (0.003)

0.003 (0.003)

−0.001 (0.001)

Data are estimated coefficients (SEM).
†
The HIV load was divided into three categories: <50, between 50 and 1,000, and >1,000.
¶ Abs, absolute values.
*p-values < 0.05. VACC, Valley AIDS Council Cohort.

(427) cells/mm3 , and the mean CD4/CD8 ratio was 0.76 (0.49).
The frequency of BMI categories as defined by the WHO (11)
were as follows: normal 375 (23%), overweight 626 (38%), obesity
class I were 393 (24%), class II were 147 (9%), and class III were
97 (6%). Males had higher blood pressure and lower BMI, HDLC, CD4/CD8 ratio compared with females. Table 1 summarizes
the descriptive conditional statistics of the demographic and
clinical data and comparative analysis between the sexes
in the VACC.

given trait by using the available data for description. Please
note that the use of a value was conditioned by the presence
of other variables (for example, the descriptive tables for age
require the presence of sex and age from a specific sample;
meanwhile, the simple description of sex in the same sample was
not conditioned by the presence of age) giving slightly different
mean values from descriptive tables and the text. The median
number of visits was 8 (Q1 5.3, Q3: 9.2) for each individual. The
following data were available: sex (1,362/1,707; 80% male) and
T2D status (917/1807; 51%). The mean (SD) age was 42.1 (12.7)
years old, BMI 29.4 (6.1), HDL-C 44.5 (12.7) mg/dL, LDL-C 96
(25) mg/dL, triglycerides 176 (121.6) mg/dL. The most common
treatment was integrase stand transfer inhibitors (INSTIs) in any
combination was 64% (918/1,425) of the PWH in the VACC. The
most frequent combination was INSTI+Nucleoside/Nucleotide
reverse transcriptase inhibitors (NRTI) in 22% (317/1,425) of the
individuals. Other treatment regimens used were combinations
containing Protease inhibitors (PIs) and NRTI + Non-nucleoside
reverse transcriptase inhibitors (NNRTI). The absolute CD4+
counts were 589 (315) cells/mm3 , absolute CD8+ counts 909

Frontiers in Medicine | www.frontiersin.org

HIV-1 Related Indices and Their Relation to
VACC Metabolic Traits
We then evaluated several HIV-1 related indices in the VACC and
their relationship to various metabolic traits. Eighty percent of
the VACC individuals had viral loads lower than 50 copies/mL
(N = 1,182), six percent showed viral loads between 50 and
1,000 copies/mL (N = 92), and fourteen percent showed >1,000
copies/mL (N = 212). The virus load was an independent
predictor of CD4+ counts, CD8+ counts, % CD4, % CD8, and
CD4/CD8 ratio adjusted by age, sex, presence of T2D, lipid
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FIGURE 1 | Violin plot of the relationship between CD4/CD8 ratio and viral load. Square root transformed CD4/CD8 ratios are shown on the y-axis which decrease as
a function of increasing viral loads (<50 copies, 50–1,000 copies and >1,000 copies) shown on x-axis [b = −0.13 (se 0.01), p < 0.001].

+ NNRTI and any combination regimens with PIs did not
show association with T2D (Table 4). When stepwise logistic
regression was used, with adjustment for sex, age, BMI, virus
load, and treatments to explain the presence of cardiometabolic
risk factors (dichotomous variables described in the method
section), T2D was associated with viral loads >1,000 [OR: 1.56
(95%CI: 1.09, 2.22), p = 0.014], and CD4 lower than 500 [OR:
1.36 (95%CI: 0.96, 1.93), p = 0.088]. Any treatment with INSTIcontaining combination was associated with LDL-C [OR 0.62
(95%CI: 0.48, 0.80), p < 0.001], systolic blood pressure [OR 0.71
(95% CI: 0.54, 0.95), p = 0.021] and, triglyceride concentration >
150 mg/dL [OR: 0.85 (95%CI 0.67, 1.07)].

concentration, and duration of enrollment in the clinic (Table 2).
There was no difference in viral loads between men and women
(p = 0.34). Figure 1 shows a violin plot depicting the relationship
between CD4/CD8 ratio and viral load, and as expected,
higher viral loads were negatively associated with CD4/CD8
ratios. We also found that increasing BMI was positively
associated with increasing CD4+ cell counts (Figure 2). T2D
was found in 51% of the VACC individuals (917/1,807), with
no differences by sex (females OR = 0.89, 95%CI: 0.68, 1.13;
p = 0.306). However, for example, participants with T2D had
higher CD8+ cell % (Cohen-d 25.6%, p < 0.001) and less
LDL-C (Cohen-d 0.24, p < 0.001) compared to those without
T2D (Table 3).

Comparative Analysis of Metabolic Traits
in the VACC and Other MA Populations

Association Between ART Regimens and
T2D in VACC

We have limited our comparisons between cohorts to the
currently available data from the VACC. Both HHANES and
SAMAFS have a higher proportion of female participants when
compared to VACC. The mean (SD) differences between the
VACC, HHANES and SAMAFS individuals in the traits shown
below are: BMI, 29.4 (6), 30.9 (6), and 31.1 (7) (p < 0.001);
triglycerides, 176 (121), 137 (109), and 151 (140) mg/dL (p <
0.001); and HDL-C, 44 (13), 53 (15), 48 (14) mg/dL (p < 0.001),

ART was associated with decreased viral load and increased
CD4+ T cell counts but not with metabolic dysfunction.
However, individuals on different ART regimens showed
differences in the association with T2D (Table 4). Notably,
we found that individuals on any combination regimen with
INSTI were associated with increased risk to T2D [2.08 (95%CI
1.67, 2.6; p < 0.001)]. Other treatment regimens like NRTI

Frontiers in Medicine | www.frontiersin.org
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FIGURE 2 | A histogram depicting an increase of absolute CD4 lymphocytes with an increase of body weight. The regression with CD4+ T cell counts (square root
transformed) was b = 0.48 (robust HC3 se = 0.16), p = 0.004. NW, normal weight; OW, overweight; OB-C1, obesity-category 1; OB-C2, obesity-category 2; and
OB-C3, obesity category 3.

TABLE 3 | Descriptive statistics of the VACC individuals stratified by T2D status¶ .
Variables

All Individuals
N

No T2D

T2D

Mean ± SD

N

Mean ± SD

N

p-value

Mean ± SD

Age (years)

1,500

43 (12.7)

759

42.1 (12.3)

741

43.8 (13)

0.01

BMI

1,428

29.5 (6.1)

728

29.9 (6.3)

700

29.1 (5.9)

0.021

SBP (mmHg)

1,466

129.2 (12.9)

744

129.1 (12)

722

129.3 (13.8)

0.804

DBP (mmHg)

1,466

80.8 (7.6)

744

81.1 (7.3)

722

80.5 (7.8)

0.095

Triglycerides (mg/dL)

1,423

177.8 (124.1)

598

173.1 (99.6)

825

181.3 (139.1)

0.218

HDL-C (mg/dL)

1,422

44.5 (12.7)

598

45.1 (12.3)

824

44.1 (12.9)

0.147

LDL-C (mg/dL)

1,411

96.7 (28.4)

594

100.6 (27.5)

817

93.9 (28.7)

<0.001

CD4/CD8

1,403

0.75 (0.49)

588

0.8 (0.49)

815

0.72 (0.49)

0.003

Abs CD4 per mm3

1,402

587.9 (316.7)

587

618.1 (314.2)

815

566.2 (317)

0.002

Abs CD8 per mm3

1,380

910.4 (429.9)

577

898.6 (408.4)

803

918.8 (444.9)

0.389

CD4%

1,401

27.3 (11.2)

586

28.2 (10.8)

815

26.6 (11.5)

0.008

CD8%

1,380

43.6 (12.8)

577

41.7 (11.6)

803

44.9 (13.4)

<0.001

¶ VACC,

Valley AIDS Council Cohort, SBP, Systolic blood pressure; DBP, Diastolic blood pressure; Abs, Absolute values.

organized by sex from SAMAFS and HHANES individuals are
shown in Supplementary Tables 1, 2. Both sexes showed Cohend >0.3 for diastolic blood pressure and HDL-C, and about 0.2
for BMI and triglycerides, with men showing a lower effect

respectively. This post hoc analysis was done with Tukey-Kramer
for pairwise comparisons, all adjusted for sex, age, and T2D.
Thus, the VACC individuals had lower BMI but significantly
higher triglycerides and lower HDL-C. Descriptive statistics

Frontiers in Medicine | www.frontiersin.org

6

July 2021 | Volume 8 | Article 676979

Lopez-Alvarenga et al.

T2D in HIV+ Mexican Americans

TABLE 4 | Treatments used and association with T2D in the cross-sectional analysis of VACC¶ .
Treatment

T2D

No T2D

OR (95%CI)

p-value
<0.001

Any INSTI/other

510/190 (56)

408/317 (44)

2.08 (1.67, 2.05)

Any PI/other

36/664 (51)

34/691 (49)

1.1 (0.69, 1.76)

0.692

NRTI+NNRTI/other

45/655 (46)

52/673 (54)

0.89 (0.59, 1.34)

0.577

¶ VACC, Valley AIDS Council Cohort; INSTI, Integrase Strand Transfer Inhibitor; PI, Protease Inhibitors; NRTI, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNRTI,
Non-Nucleoside Reverse Transcriptase Inhibitors.

TABLE 5 | General description and stratification by T2D status of selected variables from the SAMAFS¶ .
Variable

All Individuals

No T2D

T2D

p-val

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

Age (years)

2,498

47.4 (17.2)

1,826

43.2 (16.3)

672

58.8 (14.3)

BMI

2,475

31.1 (7.4)

1,814

30.4 (7.2)

661

32.9 (7.5)

<0.001

SBP (mmHg)

2,260

126.9 (19.3)

1,609

123.2 (17.1)

651

135.9 (21.5)

<0.001

DBP (mmHg)

2,260

71.6 (10.5)

1,609

71.5 (10.2)

651

71.9 (11.1)

0.398

Trigly (mg/dL)

2,433

150.9 (141.1)

1,779

134.6 (119.0)

654

195.2 (181.5)

<0.001

HDL-C (mg/dL)

2,432

47.8 (13.7)

1,779

48.8 (13.6)

653

45.3 (13.7)

<0.001

<0.001

¶ SBP,

Systolic blood pressure; DBP, Diastolic blood pressure; Trigly, triglycerides. SAMAFS, San Antonio Mexican American Family Studies; SBP, Systolic blood pressure; DBP, Diastolic
blood pressure; Trigly, triglycerides.

TABLE 6 | General description and stratification by T2D status of selected variables from the HHANES¶ .
Variable

All Individuals

No T2D

T2D

N

Mean ± SD

N

Mean ± SD

p-value

N

Mean ± SD

Age (years)

1,157

48.9 (16.7)

895

45.6 (16.4)

262

60.3 (11.8)

BMI

1,127

30.5 (6.2)

880

29.9 (6)

247

32.4 (6.2)

<0.001

SBP (mmHg)

1,071

125 (19.5)

833

122.9 (18.7)

238

132 (20.5)

<0.001

DBP (mmHg)

1,071

71.7 (12.4)

833

72.2 (12.1)

238

70 (13.4)

0.015

Trigly (mg/dL)

1,142

169.3 (153)

895

161.1 (149)

247

199.3 (163.5)

<0.001

HDL-C (mg/dL)

1,140

49.9 (13)

893

50.6 (13.2)

247

47.1 (11.9)

<0.001

<0.001

¶ SBP, Systolic blood pressure; DBP, Diastolic blood pressure; Trigly, triglycerides. HHANES, Mexican American data from the National Health and Nutrition Examination Survey; SBP,
Systolic blood pressure; DBP, Diastolic blood pressure; Trigly, triglycerides.

HDL-C concentrations (Figure 3). The relationship between
the triglycerides and BMI showed the classic inverted U-shape
relationship in all three cohorts. However, the HDL-C levels
decreased by the BMI strata and were found to be lowest for the
VACC individuals (Table 7 and Figure 4).

than females. In SAMAFS, T2D showed effects greater than
Cohen-d 0.5 for age, systolic blood pressure, and triglycerides;
Cohen-d 0.37 for BMI and 0.24 for HDL-C. Tables 5, 6 show
the descriptive statistics for these traits in both SAMAFS and
HHANES individuals stratified by their T2D status.
The prevalence of T2D in VACC was 51% (i.e., 917/1,807)
compared to 27% (i.e., 672/2,498) in SAMAFS and 23% (i.e.,
262/1,157) in HHANES (p < 0.001). The males in the VACC
had a greater risk of developing T2D, which is similar to that
seen in the SAMAFS. However, the PWH with T2D in the VACC
were younger (4.7 years or 0.3 standard deviations) and had
lower BMI (BMI 2.43 units less or 3.7 standard deviations) when
compared to SAMAFS. When comparing the T2D groups and
adjusting for sex and pedigree structure, individuals in the VACC
were younger and had lower BMI, p-value < 0.0001 (Table 7
and Figure 3) but showed the highest DBP levels and lowest

Frontiers in Medicine | www.frontiersin.org

DISCUSSION
Our results suggest that the PWH in the RGV developed T2D
at a younger age when compared to HIV-negative individuals
in the SAMAFS and HHANES. There were striking differences
between the cohorts: the PWH in VACC were younger and had
lower BMI but had a higher prevalence of metabolic problems
when compared to individuals in HHANES and SAMAFS.
Furthermore, the increased T2D risk in PWH was independent

7

July 2021 | Volume 8 | Article 676979

Lopez-Alvarenga et al.

T2D in HIV+ Mexican Americans

TABLE 7 | General linear models for age, BMI, blood pressure, triglycerides and HDL-C.
Variables

Age

BMI

SBP (mmHg)

DBP (mmHg)

Triglycerides (mg/dL)

HDL-C (mg/dL)

SAMAFS¶

−2.61 (0.67)**

0.31 (0.26)*

0.67 (0.67)

−0.52 (0.47)

−24.38 (5.59)**

−2.05 (0.49)**

HIV

−2.75 (0.72)**

0.50 (0.31)

6.27 (0.71)**

7.63 (0.49)**

1.1 (6.87)

−3.11 (0.62)**

T2D

14.7 (0.92)**

2.79 (0.45)**

1185 (1.43)

−3.87 (0.95)**

28.48 (12.19)*

−3.47 (0.84)**

0.95 (1.13)

0.06 (0.55)

4.208(1.66)*

3.10 (1.0)**

22.57 (14.0)

−0.25 (1.01)

−13.12 (1.12)**

−3.51 (0.55)**

−0.95 (1.57)

3.75 (1.0)**

−12.71 (14.21)

2.24 (1.08)*

–

−1.77 (0.20)**

4.31 (0.49)**

4.19 (0.31)**

32.73 (4.72)**

−6.98 (0.37)**

Age

–

−0.02 (0.03)*

0.47 (0.02)**

0.04 (0.01)**

0.11 (0.11)

0.10 (0.01)**

OW

–

–

3.29 (0.64)**

3.26 (0.40)**

39.3 (5.29)**

−5.45 (0.57)**

SAMAFS *T2D
VACC*T2D
Male

OB-Cl

–

–

4.95 (0.68)**

5.31 (0.43)**

58.27(6.25)**

−8.61 (0.58)**

OB-C2

–

–

6.39 (0.82)**

5.51 (0.63)**

66.05 (8.16)**

−9.22 (0.68)**

OB-C3

–

–

9.69 (0.95)**

6.50 (0.63)**

47.07 (6.7)**

−9.41 (0.74)**

Const

46.27 (0.584)**

31.6 (0.391)**

95.47 (0.95)**

64.99 (0.71)**

101.30 (5.91)**

55.34 (0.78)**

¶ SAMAFS, San Antonio Mexican American Family Studies; VACC, Valley AIDS Council Cohort; OW, Overweight; OB- Cx: Obesity categories 1–3. Data are shown as beta coefficients (se).
*p < 0.05, **p < 0.01.

any regimen containing INSTI was associated with an increased
prevalence of T2D. However, in the absence of longitudinal
data, we cannot attribute this increased prevalence directly to a
specific regimen. Recent studies have shown that INSTI-based
regimens can increase T2D risk through multiple mechanisms,
including an increased deposition of central adipose tissue and
adverse effects on adipose tissue that may result in insulin
resistance (30, 31). While some PI-based regimens have been
associated with deleterious effects on insulin secretion (32),
the impact of the integrase inhibitors on insulin secretion is
not well-understood. It has been speculated that INSTIs may
disrupt insulin secretion by interacting with magnesium ions
(33) that are critical for electrical activity and insulin secretion
in pancreatic beta-cells (34). Thus, it is imperative to conduct
well-controlled longitudinal studies to understand the extent
of metabolic dysfunction associated with various treatment
regimens in the VACC to implement individualized preventative
measures to reduce future cardiometabolic risk.
Obesity is thought to be associated with a chronic
inflammatory state in the adipose tissue which is mediated
through a number of inflammatory signals/cells [e.g., M1
macrophages, inflammatory cytokines (TNF-alpha and IL6), and activated CD4+ and CD8+ T cells] (35), HIV/ART
further exacerbate this condition through further modulation
of inflammatory cytokines and mitochondrial dysfunction
(36). Prior to the introduction of the newer ART regimens,
lipodystrophy was a common feature in HIV-infected persons
(37, 38). In contrast, recent studies have shown the increasing
incidence of obesity and overweight in this group, which can
be as high as 70% (39–43). In contrast to these findings, VACC
individuals had a lower mean BMI when compared to individuals
enrolled in SAMAFS, HHANES and RGV-based cohorts or their
subsets (9, 44). However, in contrast to some RGV-based HIVnegative cohorts (9), we did not find a difference in the obesity
prevalence in the diabetic and non-diabetic individuals in the
VACC. Hernandez-Romieu et al. also found similar trends in

of BMI. Patients with better virological control, irrespective of the
treatment regimen, had a more favorable metabolic profile.
Previous studies have shown that insulin resistance and
T2D prevalence are increased in individuals who have HIV-1
infection (3). However, there are only limited studies that have
examined the prevalence of HIV and T2D in the RGV region.
A recent analysis by De La Garza et al. showed that the average
HIV incidence rates increased by 115% per 100,000 within the
RGV from 2007 to 2015, which is higher than other Texas
counties with large populations (26). RGV region also has a high
prevalence of adult T2D and has been estimated to be as high
as 30.7% compared to a nationwide prevalence of 12.3% (8, 9).
Remarkably, Restrepo et al. found that the prevalence of T2D
in individuals affected with tuberculosis in the Cameron and
Hidalgo counties to be 39% (27). The presence of preexisting
metabolic diseases and the de novo metabolic complications due
to HIV-1 infection and ART could contribute to unusually high
T2D prevalence seen in the VACC.
While recently introduced ART regimens have greatly
improved metabolic outcomes, there have been reports of
persistent metabolic dysfunction in PWH (28). For example,
a longitudinal study conducted by Gomes et al. suggests that
ART may increase T2D risk in Hispanics (25). They examined
the development of new-onset impaired fasting glucose (IFG)
following ART initiation in PWH in a Dominican HIV Hispanic
cohort who were initiating ART (N = 153; ≤ 180 days prior
to starting ART). At baseline, they found that 6% had T2D
and 16% had IFG. Strikingly, in this cohort, 46 developed IFG
after 329/1,000 person-years follow up. Most of the individuals
developed metabolic complications within 12 months following
the ART start, although only 13% were on PIs. Recent data also
suggests that ART regimens that are initiated with INSTIs or
PIs may confer a greater T2D risk, and this may be mediated
through weight gain (29). They also reported that this effect is
more pronounced in raltegravir-based initiators when compared
to those based on NNRTIs. Our findings in VACC suggest that
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FIGURE 3 | Violin plots depicting the relationship between T2D status and various demographic and cardiometabolic traits in the VACC and HIV-1 negative HHANES
and SAMAFS individuals. (A) Violin plot showing relationship between T2D status and age in the three cohorts. Participants with T2D were older than non T2D [b =
13.1 (se 1.3), p < 0.001], but the VACC individuals showed interaction with T2D [b = −9.5 (se 1.9), p < 0.001]. (B) Violin plots showing relationship between age-,
sex-, and cohort-adjusted BMI and T2D status in three different cohorts. Higher BMI was associated with T2D status [b = 2.8 (se 0.45) p < 0.001] in HHANES and
SAMAFS, but interaction between VACC and T2D shows lower BMI when compared with other cohorts [b = −3.5 (se 0.55) p < 0.001]. (C,D) Violin plots showing
relationship between SBP and DBP adjusted by age, sex, cohort, BMI and T2D status. For VACC, there was an interaction seen for DBP [b = 3.8 (se 1.0) p < 0.001],
but not for SBP. (E,F) Violin plots showing relationship between triglycerides and HDL-C adjusted by age, sex, cohort, BMI and T2D status. T2D was associated with
higher triglycerides concentrations [b = 28.2 (se 12.3), p = 0.02] and lower HDL-C [b = −3.5 (se 0.9) p < 0.001]. The HDL-C showed interaction for VACC [b = 2.2
(se 1.1) p = 0.042]. HHANES: The Hispanic component of NHANES 2018 cohort; SAMAFS, San Antonio Mexican American Family Studies; VACC, Valley AIDS
Council Cohort. The continuous horizontal line represents the mean value without adjustment.
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FIGURE 4 | Violin plots showing relationship between triglycerides (A) and HDL-C (B) with BMI categories after adjusting for age, sex, cohort, and T2D status. The
presence of diabetes was associated with higher triglyceride concentration [b = 28.2 (se 12.3), p = 0.02] and lower HDL-C [b = −3.5 (se 0.9) p < 0.001]. The HDL-C
showed interaction for VACC [b = 2.2 (se 1.1) p = 0.042]. HHANES: The Hispanic component of NHANES 2018 cohort; SAMAFS, San Antonio Mexican American
Family Studies; VACC, Valley AIDS Council Cohort. NW, normal weight; OW, overweight; OB-C1, obesity-category 1; OB-C2, obesity-category 2; and OB-C3, obesity
category 3. The continuous horizontal line represents the mean value without adjustment.
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studies. Another limitation of our study is that the data
were available for only 20 months due to a recent switch
from a different electronic medical records database. Future
studies will incorporate these additional factors and longitudinal
designs to gain further insights into T2D pathogenesis in
the VACC. Nevertheless, our analyses recapitulated several
key aspects of HIV disease pathogenesis, including an inverse
relationship between viral load and CD4+ cell count and
CD4/CD8 ratio, thus suggesting our cross-sectional data are
highly informative.
In summary, the prevalence of T2D in the PWH in
the Rio Grande Valley is higher than the national and
South Texas Hispanic populations. Remarkably, this increased
prevalence is not associated with a higher BMI, suggesting that
factors independent of obesity may be in part responsible for
disease pathogenesis. Despite their lower BMI, these individuals
showed increased dyslipidemia and hypertension, reflecting
poor metabolic health. Further cross-sectional and longitudinal
studies are necessary to develop personalized interventions to
improve metabolic health and reduce future cardiovascularrelated morbidity and mortality.

the NHANES individuals. Using 2009–2010 data, they found
that diabetes prevalence is much higher in HIV-infected adults
when compared to the general U.S. adult population in the
absence of obesity (45). Also, they also found that HIV-infected
individuals had a higher prevalence of diabetes at younger
ages. This higher T2D prevalence in PWH may be related to
a chronic inflammatory state induced by HIV-1 infection and
ART-induced insulin resistance.
Recent studies have suggested that the major classes of
ART have differential effects on weight gain (31, 46–50) and
abnormalities in fat and lipid storage (51). For example, Menard
et al., reported that there was a mean weight gain of ∼3 kg in
a cohort (N = 462) receiving an integrase inhibitor-based ART
regimen (dolutegravir) after a follow-up of an average of 276 days
(46). Using a large study population (ACTG A5257 clinical trial;
N = 1,809) in which the treatment naïve HIV were randomized
into three different treatments: raltegravir (integrase inhibitors)
or atazanavir/ritinovir (PIs) or darunavir/ritonavir (PIs), all in
combination with tenofovir disoproxil fumerate/emtricitabine,
Bhagwat et al., reported that blacks on integrase inhibitors had
larger increases in waist circumference when compared to nonblacks (31). In the same study, they found that women had a
greater increase in waist circumference when compared to men.
In the VACC, we could not find any relationship between obesity
prevalence and the broad ART regimens, and future longitudinal
studies are needed to understand this phenomenon. Remarkably,
we found that increasing BMI had a positive association with
absolute CD4+ cell counts. This finding is in agreement with a
previous study that also showed a positive relationship between
higher BMI and CD4+ cell recovery in HIV-1 infected people
on ART (52). Notably, such a positive relationship between
higher BMI levels and CD4+ counts is also described in the
absence of HIV-1 infection (53). The relevance of such an
increase in CD4+ counts with increasing BMI in PWH needs
additional studies.
Our study has some important limitations that are commonly
encountered when extracting data from clinical records,
including missing data, unavailability of records that are relevant
for metabolic diseases such as waist circumference, physical
activity, dietary habits, acculturation factors, co-infection with
HCV, mode of disease transmission, prediabetes, among others.
An important limitation is that we have relied on BMI as a major
determinant to assess metabolic health in the VACC individuals
in absence of other more appropriate obesity measures. While
body composition measures such as waist circumference and fat
mass would be more suitable to assess metabolic dysfunction in
non-obese PWH due to HIV and ART-induced fat alterations,
BMI categories have been successfully used to evaluate metabolic
health in absence of such measures. For example, Lake et al.
showed that in the Multicenter AIDS Cohort Study (MACS)
normal weight and overweight HIV-positive men are much
less likely to be metabolically healthy when compared to nonobese HIV-negative men (54). Given that the recent reports
suggest that integrase inhibitor-based regimens could result
in increased accumulation of both subcutaneous and visceral
adipose tissue (55), we plan to conduct additional assessments
for body composition in the VACC participants for future
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